Sorry, but the browser version you are currently using is not supported by this website. We recommend that you update or download a more recent version.


The digital
for people
with Type 2
diabetes and
their care teams


We innovate


by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

We innovate

healthcare solutions

by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.


Voluntis was founded in 2001 by three entrepreneurs who believed that innovative medical solutions built with advanced information technologies would improve medical real-life outcomes and thus increase healthcare system efficiency. This would transform patient lives, enhance medical practices and quality of care.

Every day, Voluntis teams seek to invent secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-oriented processes. With more than 600,000 patients managed and more than 50 programs deployed, our track record speaks for itself.

  • 600,000
    patients managed
  • 50
    programs deployed

At Voluntis, we are all guided by clear and simple values:

  • Patient focus: we are committed to changing the daily lives of patients by addressing their unmet needs and by empowering them to manage their chronic conditions.
  • Passion for innovation: we design next-generation solutions that combine digital and medical expertise to solve the daily problems of patients and caregivers.
  • Respect and integrity: everyday, we take care of the people we touch, our patients, customers, partners and employees.
  • Drive for excellence: in everything we do, we behave ethically and we strive to attain the highest level of quality. Always working to enhance our processes, we are certified ISO 9001 and ISO 13485 (regarding quality management systems). We are also compliant with ISO 14971 standards (risk management). Our design methodologies embed the harmonized IEC 62304 and IEC 62366 standards (for medical device software).
Alexandre CAPET

Alexandre CAPET

Chief Strategy & Marketing Officer and Member of the Management Board

Before joining Voluntis, Alexandre worked 15 years in the pharmaceutical industry. At Sanofi, he notably headed the Group's strategic planning and M&A for France, where he strongly contributed to building the Diabeo partnership with Sanofi, CERITD and Voluntis. Alexandre is a graduate of HEC Paris and Sciences Po Paris. He holds a master's degree in health economics from Paris-Dauphine University.



Chief Executive Officer, President of the Management Board and Founder

Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.



Chief Operations Officer, Co-Founder and Member of the Management Board

Romain is Chief Operations Officer of Voluntis and heads the company’s North American operations in Cambridge, MA. He has more than 15 years of experience in digital health and software medical devices. He holds an MSc from École Centrale Paris in applied mathematics.

Matthieu Plessis

Matthieu PLESSIS

Chief Financial Officer

Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position, he successfully supported the group’s rapid growth as well as it’s finance and M&A operations. Previously, he worked for Glaxo and SFR-Cegetel. He is a graduate of ESSCA management school.

Dr Geneviève D'ORSAY

Geneviève D'ORSAY

MD, Chief Medical Officer

Geneviève has more than 20 years of experience in the life sciences industry. Before joining Voluntis, she was Medical Affairs Director for Johnson & Johnson Medical Devices & Diagnostics for France & BeNeLux. Prior to this position, she worked for Altana Pharma, Chiesi and Bioprojet. She holds a doctorate in medicine and a degree in pharmacology and clinical research from University of Paris VI as well as a degree in pharmacovigilance from University Descartes, Paris.

Matthieu Plessis

Matthieu PLESSIS

Chief Financial Officer

Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position he successfully conducted an IPO in Europe, as well as the trade public to private sale of the company. Previously, he worked for Glaxo, SFR-Cegetel and Cegetel Enterprises. He is a graduate of ESSCA management school.

Etienne VIAL

Etienne VIAL

Vice President Innovation and Co-Founder

Etienne manages the innovation activities at Voluntis. Etienne has more than 12 years of experience in building frameworks, deploying m-health solutions and developing algorithms, analytic suites and interoperable software. He is a graduate of the École Centrale Paris engineering school.

Patrick Alff

Patrick ALFF

Vice President Engineering and Services

Patrick heads our Engineering and Services department where he leverages his solid international management experience, with a heavy emphasis on the development of enterprise software and cloud services. Former Head of Technology Strategy at British Telecom, Director of Technology at Infonet in California, VP of R&D and Innovation at OpenTrust and IT transition manager with several other companies, Patrick is keen to promote change, innovation and customer satisfaction. He enjoys combining his entrepreneurial spirit with his passion for technology and management.



Vice President Quality & Regulatory Affairs

Raffi has 15+ years of experience in the medical device industry. Prior to joining Voluntis, Raffi was Manager at Hutchinson Santé, healthcare subsidiary of Hutchinson Group, where he headed R&D, manufacturing and regulatory affairs in an international environment. Raffi is a graduate of the Ecole Nationale Superieure de Chimie de Mulhouse and holds a PhD in polymer science. He also holds an MBA from ESCP Europe business school.



Vice-President Real-World Evidence

Damien is charged with extending Voluntis' real-world evidence capabilities, notably in the fields of outcomes measurement and data valuation. He trained in the UK as a pharmacist and computer scientist. He has over 15 years of experience in the pharmaceutical industry and in frontline clinical healthcare (at Portsmouth Hospitals NHS Trust and multiple pharmacies). He notably worked at AXA, where he helped build an operational framework to handle outsourced medical information services for pharmaceutical partners. In 2005 he led the preparation for the first ever UK Medicines and Healthcare Products Regulatory Agency inspection of this type of provider. He joined Voluntis in Paris in 2008 to take the helm of its quality division, obtaining QMS certification for ISO:13485 in 2010 and VITM/Diabeo’s CE Mark in 2013.



Senior Vice President Payer Sales & Strategy

Scott is accountable for building, developing, and operating partnerships with payer organizations in the U.S. market. He has over 15 years of experience working closely with payers in sales, client management, and clinical product development capacities. Prior to joining Voluntis, Scott held leadership roles in sales and client management at Omada Health, he led the clinical consulting team at Catamaran (now OptumRx), and he started his career in managed care pharmacy at Mayo Clinic Health Solutions. Scott received PharmD and MBA degrees from Creighton University as well as a BA in Chemistry from Central College.

  • Pierre LEURENT

    Chief Executive Officer, President of the Management Board and Founder


  • Romain MARMOT

    Chief Operations Officer, Co-Founder and Member of the Management Board


  • Etienne VIAL

    Vice President Innovation and


  • Alexandre CAPET

    Chief Strategy & Marketing Officer and Member of the Management Board


  • Dr Geneviève D'ORSAY

    Chief Medical


  • Scott Honken

    Senior Vice President Payer Sales & Strategy


  • Matthieu Plessis

    Chief Financial


  • Patrick Alff

    Chief Technology



    Vice President Quality & Regulatory Affairs


  • Damien MCKEON

    Vice-President Real-World Evidence



Formed by the law of 31 December 2012, Bpifrance (a public sector investment bank) is the outcome of the merger between OSEO, the FSI, CDC Entreprises and FSI Régions. Its two shareholders are the French state and the Caisse des Dépôts bank. Its objective is to support businesses (small and medium-sized enterprises and larger companies of a strategic importance to the French economy), from start-up through to stock market flotation, by providing loans, guarantees and equity. Bpifrance also provides enhanced support and backing for innovation, export and external growth. With its 42 regional offices, it is a one-stop shop for entrepreneurs in each region for all their finance and investment needs.
Follow them on Twitter: @bpifrance

LBO France

As a key player in private equity with €3.4bn of capital under management, LBO France is an independent company that has been supporting French and Italian companies in their growth for more than 30 years. Its strategy is based on four investment approaches in non-listed assets, managed by dedicated teams: (i) Mid Cap Buyout through the White Knight funds and Small Cap Buyout through the Hexagone / Small Caps Opportunities funds, (ii) Venture Capital through the SISA fund, (iii) Real Estate through the White Stone and Lapillus funds, (iv) Debt. LBO France is 100%-owned by its management and employs nearly 60 professionals.


Vesalius Biocapital is a pan-European venture capital group investing in early stage innovative biotech companies. Most of its investments consist of therapeutic companies developing new drugs and devices. Vesalius’ total fund size is €160 million. The team is composed of experienced life science experts and business people.

Qualcomm Incorporated

Qualcomm Incorporated is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm’s licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm’s engineering, research and development functions, and all of its products and services businesses, including its semiconductor business, QCT. For more than 25 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.

CM-CIC Innovation

CM-CIC Innovation specializes in venture capital tech investments. In addition to Sudinnova, it supports the development of companies with strong growth potential in dynamic sectors such as information technologies, healthcare, industrial innovation and the environment. CM-CIC Innovation is a subsidiary of CM-CIC Capital Finance, the investment wing and merchant bank of the Crédit Mutuel-CIC Group. With €2.6 billion in capital (including €1.9 billion in equity), a portfolio of 630 companies and six regional branches throughout France (Paris, Lyon, Nantes, Lille, Strasbourg and Bordeaux), CM-CIC Capital Finance is one of the few merchant banks that invests its own funds for the long term.

CapDecisif Management

CapDecisif Management manages CapDecisif, FCPR CapDecisif 2 and G1J Ile-De-France: early-stage venture capital funds sponsored by Bpifrance, the Ile-de-France region and BNP. Since 2002, the management team has invested in 32 new information technology companies in software, the life sciences, biotech, energy and the environment, and the engineering sciences. CapDecisif Management currently manages almost €100 million.


Founded in May 2014, Sham Innovation Santé is a venture capital fund controlled and held by Sham, a French mutual insurance company that specializes in risk management for health care, social welfare and community health organizations. SHAM, which is one of the French leaders in its sector, has a portfolio of assets of €1.8 billion invested in several asset classes (bonds, real estate, listed securities, private equity, etc). Advised by Turenne Capital, Sham Innovation Santé’s mission is to support the growth and development phases of young innovative businesses in the health industry.

Eric Elliott

Chairman of the Board

In his most recent role as Prime Therapeutics' President and Chief Executive Officer, Eric Elliott was responsible for all operating and strategic aspects of the full service pharmacy benefit management company. With approximately $17 billion in annualized drug spend under management, Prime Therapeutics is the fourth largest pharmacy benefit manager in the United States, servicing 23 health plans, other smaller pharmacy benefit managers (PBMs), and employer direct customers. Critical to the success of Prime Therapeutics, Eric led the partnership with Blue Cross and Blue Shield Plans to ensure members receive the highest quality of care while managing appropriate pharmaceutical costs and trends. Under Elliott's leadership, Prime was recognized locally and nationally by prominent publications and organizations for its employee engagement, healthy workplace, highest quality and care of service for members, and business growth. With experience running three integrated PBMs, Eric is skilled in leading and growing businesses to include line and segment expansions. He previously served as president of Cigna's Pharmacy Management and Voluntary businesses and has held senior executive level positions at Aetna, PCS HealthSystems and Rite Aid Corporation. Elliott received his bachelor's degree in management and finance, and a Master of Business Administration from Temple University in Philadelphia. He has served for many years on the board of directors at Prime, The Main Street America Group, the Pharmaceutical Care Management Association and the Twin Cities American Heart Association. Elliott also serves on The Wall Street Journal CEO Council.

Nicolas Cartier

Vice Chairman of the Board and Member of the Remuneration Committee

Nicolas Cartier is Corporate Vice President, Industrial Microbiology Unit of bioMérieux and member of bioMérieux’s Executive Committee. Before joining bioMérieux, Nicolas was General Manager of Sanofi France from 2009 to 2013. Prior to that, he held various internal positions within Sanofi, in particular in Thailand, where he was in charge of commercial development for the Southeast Asia region within the Animal Health Division; in Shanghai, where he headed up Sanofi China’s Pharmaceutical Division; and in Mexico City, where he was General Manager of Sanofi Mexico. In addition, Nicolas was Chief of Staff of the Chairman and CEO of Sanofi. Nicolas is a graduate of École Polytechnique, École des Ponts and Institut d’Études Politiques de Paris.

Emilie Lidome

Board Member and Member of Remuneration Committee

Emilie Lidome has a biological engineering & management of enterprise background, and joined the venture capital field in 2008. Investment Director at CM-CIC Capital Innovation, a subsidiary of the Crédit Mutuel - CIC group's investment and merchant bank division, she invests in high technology companies. Before joining CM-CIC Capital Innovation, she worked in the biotechnology & pharmaceutical industries. She led fundamental research projects and has carried out missions of departments’ coordination consulting in companies such as Novartis or GSK. Emilie Lidome has a degree in biological engineering from the Université de Technologie de Compiegne and holds a Master Degree in Management of Biotechnology Companies from Grenoble Ecole de Management.

Jean Bertin

Board Member and Member of the Audit Committee

Jean Bertin is an Investment Principal at Bpifrance Large Venture, a €600m vehicle investing in high-growth innovative companies with significant capital requirements (>€20m) in the Healthcare and Tech spaces. Since he joined Large Venture in 2013, he focuses and accompanies portfolio companies in the digital and medtech sectors and has invested in Voluntis, Scality, Biom’up, Pixium Vision and Isorg. He has been active in the startup environment for the past 7 years, first as an intern at Naxicap Partners then as a project manager for a solar PV developer and business development consultant for a desalination company. He then joined the Caisse des Dépôts group as an investor in the cleantech sector at CDC Climat. Jean Bertin holds an MBA from ESSEC Business School (Paris/Singapore).

Alain Parthoens

Board Member

Alain Parthoens is co-founder and managing partner of Vesalius Biocapital funds I & II. He launched his first pan-European life science venture capital fund end of 2007 (VBC I, €76M raised) invested in 11 life science companies. In 2011, Vesalius raised its second fund (VBC II), reaching €78M which has permitted investments in six companies for the time being. Alain Parthoens has 12 years of experience as a venture capitalist with Vesalius Biocapital as well as ING Bank, where he was the life sciences investment director for southwestern Europe. Since 2001, he has invested in almost 30 early stage life science companies, most of the time in a leading role. As board member, he has actively participated in the development of several of them. Additionally, Alain Parthoens has many years of international experience working with food and life science companies, such as Nestlé, Kemira and Monsanto, and as an R&D consultant for pharmaceutical companies with PriceWaterhouseCoopers in London. He was the chairman of the Belgian Venture and Private Equity Association. He is now a member of EVCA VC Council. Alain holds an MSc in agronomy and specialty biochemistry from the Université Catholique de Louvain, an MSc in finance and computer sciences from Université Libre de Bruxelles and a management degree from the Solvay Business School.

Benoît Pastour

Board Member and Member of the Audit Committee

Before joining Turenne Capital in 2008, Benoit Pastour spent 17 years at Vauban and at Participex as an Account Manager, Chief Investment Officer and Associate Partner. Prior to that, Benoit Pastour was head of LBO Financing at Crédit Agricole. Benoît is also Vice-Chairman of Nord Capital Partenaires and in charge of the Healthcare division with Mounia Chaoui. Benoit is a graduate of IESEG and holds a Masters in Economics from Université Paris II.

Franck Noiret

Board Member and Member of the Remuneration Committee

Franck Noiret is Managing Director of Innovation Capital at LBO France, a leading private equity firm with over 3 billion euros under management. He joined Innovation Capital in 2005 as General Partner, and LBO France in 2016 when the firms joined forces. He is currently investing in Digital Health companies in Europe through the Services Innovants Santé et Autonomie (SISA) fund. With over 20 years of investment experience in Technology and Healthcare, Franck Noiret is currently board member of Voluntis, Entrepreneurs & Investisseurs Technologies, Kayentis, Omni Orthopaedics (US), Zesty (UK) and observer of Ekinops (EKI / Euronext). Prior to joining Innovation Capital, Franck Noiret was Director at Apax Partners in Paris where he was responsible for investments in Technology and Telecoms ranging from venture capital to growth LBO. From 1995 to 2000, Franck Noiret was Principal Banker at the European Bank for Reconstruction and Development (EBRD) where he was responsible for private and public sector investment projects in Central and Eastern Europe. De 1989 à 1993, Franck Noiret was a banker in the City of London for Société Générale after starting his career as an auditor at Arthur Andersen in Paris. Franck Noiret has a MBA from the Wharton School (US) and a Master in Corporate Finance from Paris-Dauphine University. He graduated with the highest distinction from Sciences Po Paris.

Catherine Boule


Catherine Boule serves as a Partner and Member of the Management Board at CapDecisif Management SAS. She is responsible for CapDecisif Management investments in the healthcare sector. Catherine worked previously at the Curie Institute in Paris and for a high-tech incubator. She serves as a non-executive director of different companies within the portfolio of CapDecisif Management, including Echosens. She holds an MSc in Molecular Biology from Paris University and a Master's Degree in the Management of Biotechnologies.

Timothy Jackson


Timothy is a Manager of Finance at Qualcomm Ventures focusing on early stage investments. He is also responsible for market investment analysis, due-diligence, and deal execution for Qualcomm Ventures. Prior to joining Qualcomm Ventures, Timothy worked in Qualcomm’s corporate finance division as an analyst in Financial Planning and Analysis as well as the Legal and Patent organization. Timothy holds a BS in finance from Boston College, a JD from the UCLA School of Law, and an MBA from UC San Diego’s Rady School of Management.


We firmly believe that the unprecedented advancement of information
technologies will contribute to solving certain healthcare system issues,
notably related to chronic disease expansion.

At Voluntis, we believe these remarkable changes are the pivotal factors that are already transforming healthcare systems. We are poised and ready to catapult the best from advanced technologies to improving healthcare.

Committed to this vision, Voluntis designs digital therapeutics that transform healthcare by:

  • designing integrated care services
  • aligning the interests of patients, providers and payers
  • driving costs down while improving quality
  • establishing a collaborative relationship between patients and their doctors



At Voluntis, we develop state-of-the-art digital therapeutics to accompany
and enhance a specific medication or medical device.

We design our digital therapeutics in a user-friendly manner
to augment the real-life value of therapeutics by:

For example, we design clinical algorithms that support decision-making, such as medication dosage.

For example, we securely connect patients with caregivers to activate remote operations, such as monitoring, treatment adjustment or coaching.

For example, we promote data sharing between doctors and patients to foster engagement and enable effective task delegation among healthcare professionals so as to optimize time.

As an accompaniment to existing medication or medical devices, digital therapeutic apps aim to monitor side effects, guide symptom management, promote protocol adherence, recommend dosage or connect patients with their healthcare teams.

According to prevailing regulations, our digital therapeutics could be classified as a software medical device. To strictly comply with regulations, Voluntis has developed extensive regulatory expertise and implemented high quality standards.

As such, digital therapeutics have the potential to empower patients, prevent complications and, ultimately, augment the real-life value of a medication.

We conduct clinical studies to demonstrate the value and medical benefits of our digital therapeutics. In the diabetes m-health field, our digital therapeutic solution is the most extensively studied on the market.

Voluntis develops proprietary digital therapeutics but also provides partners with development and regulatory capabilities to elaborate their own.


Theraxium is a comprehensive and highly flexible platform that transforms health data into medical intelligence for better care.

Voluntis develops proprietary digital therapeutics but also provides partners with development and regulatory capabilities to elaborate their own digital solution based upon its Theraxium core system architecture.

Operated on the Cloud, Theraxium is a modular
web-based and mobile platform that can:

Management of device interoperability and seamless integration.

Security management and compliance with privacy rules.

Through configurable roles and workflows to coordinate the activities of care providers.

Analysis and retrieval of relevant information, using an analytics suite that incorporates clinical algorithms, automated notification or dashboards to support medical decisions.

Automated effective recall of software medical devices.

The cornerstone

A modular platform, Theraxium enables healthcare organizations to monitor patients remotely, support patient assistance programs (therapeutic education for instance), track adverse events and prompt compliance.

Theraxium is also the cornerstone of our digital therapeutics. Tailored to design mobile applications, Theraxium is the underlying platform of our solutions dedicated to diabetes, respiratory diseases, cancer, hemophilia and anticoagulation.

Proven reliability

A highly flexible framework, Theraxium has proven its reliability through its implementation in 50+ programs covering more than 20 therapeutic fields. Six top 10 pharmaceutical leaders have deployed Theraxium to support patient-centric initiatives. It has provided support and monitoring to over 610,000 patients in 12 countries.

With over 50 e-health and m-health projects deployed, the Voluntis team has developed a unique expertise in developing software medical devices.

We combine flexibility with regulatory compliance; our quality certified project methodology aims to deliver state-of-the-art products and solutions by following the Agile Manifesto, relying on an interactive approach that encourages:

  • interaction
  • task parallelization
  • responsiveness
  • and customer collaboration

Beyond being your single point of contact, your Voluntis project manager ensures that your project fully meets your expectations, timeline and budget throughout design, development, validation and delivery phases.

In addition to traditional software management, your Voluntis project manager addresses all topics specific to medical device manufacturing (such as human factors, product/patient risk management and clinical evaluations) with our experts.

Focused on patient safety and driven by excellence,
Voluntis’ teams put quality at the heart of what they do.

Since 2008, our Quality Assurance department has ensured compliance with regulations and standards, trained employees in our quality processes and managed our product regulatory clearance and registration.


Our diabetes solutions are designed to support type 1 and type 2 diabetes patients throughout the insulin therapy pathway. Our digital therapeutics in diabetes are prescription medical devices.


Insulia® is a digital therapeutic for people with type 2 diabetes who are being treated with long-acting basal insulin.
Insulia is a prescription-only medical device that provides patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data. Insulia works with insulin Lantus® and insulin Levemir® and enables a wide variety of treatment plan configurations that are based on scientifically supported and well-accepted insulin adjustment rules. Insulia® is accessible to the patient via a web portal or on iOS and Android mobile devices (smartphone or tablet).

Insulia is a regulated healthcare product that was granted a CE Mark and FDA clearance in 2016. It is approved for use in the USA and the EU.

To learn more, visit insulia.com


Diabeo® is a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen. It provides therapeutic and decision-making support for effective diabetes management to help adult patients dose their basal and bolus insulin, facilitate interactions between patients and their healthcare professionals, support remote management and the implementation of telemedicine services. Diabeo® suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Diabeo® was conceived as part of an extensive clinical program including 3 clinical studies conducted in partnership with Sanofi and the CERITD over the past 10 years.

Diabeo® is a regulated healthcare product that was granted a CE Mark in 2013. Diabeo® is not approved for use in the United States.

Diabeo® is a registered trademark of Sanofi.
Insulia® is a registered trademark of Voluntis.

Our oncology solutions aim to help those afflicted with various cancers to better manage their medical care in their day-to-day lives. Prescribed by care teams as an extension of treatment, they help patients better manage their symptoms and side effects.

Breast cancer

With Roche, we are in the process of developing a digital solution for women afflicted with breast cancer. Their symptoms will be entered manually by the patient or collected automatically through connected devices in a mobile app. The data will then be automatically analyzed and sent via Internet to the patient’s medical team, which will remotely ensure personalized follow-up. Patients will then be pushed tailored recommendations to adjust their treatment thanks to the algorithmic intelligence integrated in the heart of the mobile and cloud solution.

Ovarian cancer

In close collaboration with AstraZeneca and the US National Cancer Institute (NCI), we plan to test a digital therapeutic for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. It is delivered through a smartphone app paired with a web portal that enables clinicians to help patients manage treatment side effects of hypertension and diarrhea sometimes associated with combination therapy of cediranib and olaparib. The app will be tested as a digital therapeutic in three separate clinical trials sponsored by the NCI beginning in the first quarter of 2016.


In anticoagulation treatments, compliance is crucial: the INR (International Normalized Ratio) must be regularly measured to ensure the appropriate dosage of the vitamin K antagonist treatment.

In collaboration with Roche Diagnostics, Voluntis has developed a digital therapeutic to enhance the CoaguChek INR self-testing device.

This solution, named CoaguChek Link, centralizes the INR data measured by patients, connects patients with the independent diagnostic testing facility and enables effective telemonitoring by healthcare professionals.

Thus, CoaguChek Link simplifies care delivery, ensures compliance and enables doctors and patients to stay connected and work together on managing the anticoagulant treatment.


In hemophilia, we work to help patients manage their condition. Our innovative solution aims to simplify the remote monitoring of bleeding events as well as inventory medication management.